Exelixis | EXEL - Operating Expenses


Exelixis reported $380.28M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bayer EUR 10.04B 168M Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Genmab DKK 748M 77M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Moderna USD 960M 817M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sanofi EUR 8.98B 1.73B Mar/2026
Takeda JPY 981.78B 36.71B Sep/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026